Cargando…
ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma
Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the transplant-ineligible NDMM patients when treated...
Autores principales: | Park, Sung-Soo, Lee, Jong Cheol, Byun, Ja Min, Choi, Gyucheol, Kim, Kwan Hyun, Lim, Sungwon, Dingli, David, Jeon, Young-Woo, Yahng, Seung-Ah, Shin, Seung-Hwan, Min, Chang-Ki, Koo, Jamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199943/ https://www.ncbi.nlm.nih.gov/pubmed/37210456 http://dx.doi.org/10.1038/s41698-023-00385-w |
Ejemplares similares
-
Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
por: Byun, Ja Min, et al.
Publicado: (2023) -
Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
por: Cho, Su-Hee, et al.
Publicado: (2019) -
A critical role of VMP1 in lipoprotein secretion
por: Morishita, Hideaki, et al.
Publicado: (2019) -
P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
por: Larocca, A., et al.
Publicado: (2023) -
A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
por: Kim, Youngwoon, et al.
Publicado: (2012)